Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

The combination of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) has been the mainstay of frontline treatment for classical Hodgkin lymphoma (HL) for more than 30 years. Brentuximab vedotin (BV), an antibody –drug conjugate targeting CD30, has been approved for use in patients with relapsed/refractory HL since 2011 and has gained widespread use in the salvage or consolidation after autotransplant setting. Recently, Connors et al. reported the results of ECHELON-1, an open-label, randomised phase 3 tr ial of patients with previously untreated advanced-stage HL comparing AAVD (BV, doxorubicin, vinblastine and dacarbazine) against ABVD [1].
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research